Curcumin and Homotaurine Suppress Amyloid-β_25-35 Aggregation in Synthetic Brain Membranes

Area of Science:

• Neuroscience
• Biochemistry
• Materials Science

Background:

• Amyloid-beta (Aβ) peptides aggregate into β- and cross-β-sheets within model brain membranes.
• These aggregates can grow into larger plaques, contributing to neurodegenerative diseases.
• Inhibiting Aβ aggregation is a key therapeutic strategy.

Purpose of the Study:

• To investigate the effects of curcumin and homotaurine on Aβ25-35 aggregation in synthetic brain membranes.
• To compare the efficacy of peptide-targeting versus membrane-targeting aggregation inhibitors.

Main Methods:

• Utilized optical and fluorescent microscopy, X-ray diffraction, and UV-vis spectroscopy.
• Studied the interaction of curcumin and homotaurine with Aβ25-35 aggregates in synthetic membranes.
• Assessed membrane integrity and drug partitioning.

Main Results:

• Both curcumin and homotaurine partitioned uniformly into membranes without causing defects.
• Both compounds significantly reduced the number of nanoscopic Aβ aggregates.
• Aβ aggregation signals (β- and cross-β-sheet) were notably decreased.

Conclusions:

• Membrane-active drugs, like curcumin, can be as effective as peptide-targeting drugs, like homotaurine, in inhibiting amyloid aggregation.
• Membrane-lipid therapy offers a viable alternative pathway for suppressing amyloid peptide aggregation.
• These findings support the development of drugs targeting membrane-mediated pathways for neurodegenerative diseases.